Meeting
2022 ASCO Annual Meeting
ARST2031: A study to compare early use of vinorelbine and maintenance therapy for patients with high risk rhabdomyosarcoma.
Authors
Wendy A Allen-Rhoades
Mayo Clinic, Rochester, MN
Wendy A Allen-Rhoades , Leo Mascarenhas , Wei Xue , Sarah S. Donaldson , Dana Casey , John Frederick Shern , Erin R. Rudzinski , Stephen Skapek , David A. Rodeberg , Timothy Lautz , Archana Shenoy , Irit Maianski , Sireesha Yedururi , Kim Maxa , Brian D. Crompton , Lindsey Fricke , Zhong Su , Douglas James Harrison , Rajkumar Venkatramani
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Sarcoma
Track
Sarcoma
Sub Track
Soft Tissue Tumors
Clinical Trial Registration Number
NCT04994132
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr TPS11591)
DOI
10.1200/JCO.2022.40.16_suppl.TPS11591
Abstract #
TPS11591
Poster Bd #
490b
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Risk-adapted local therapy and intensive chemotherapy in patients with high-risk rhabdomyosarcoma.
First Author: Michael W. Bishop
Poster
2011 ASCO Annual Meeting
Feasibility of vincristine, dactinomycin, and cyclophosphamide (VAC) chemotherapy for adult rhabdomyosarcoma (RMS) with regard to dose intensity (DI).
First Author: Y. Kojima
Poster
2011 ASCO Annual Meeting
Clinical outcomes in adult and childhood rhabdomyosarcoma (RMS) treated with vincristine, dactinomycin, and cyclophosphamide (VAC)/VAC-like chemotherapy.
First Author: K. Harano
Poster
2017 ASCO Annual Meeting
Rhabdomyosarcoma (RMS) in adults: Histologic subtypes and overall survival with actinomycin-based chemotherapy vs doxorubicin-based chemotherapy.
First Author: Alia Vang